Moderna, Inc. (NASDAQ:MRNA) Holdings Reduced by Northwest & Ethical Investments L.P.

Northwest & Ethical Investments L.P. lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 9.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 14,068 shares of the company’s stock after selling 1,387 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Moderna were worth $940,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. B. Riley Wealth Advisors Inc. raised its stake in Moderna by 18.6% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 9,871 shares of the company’s stock valued at $1,020,000 after acquiring an additional 1,549 shares in the last quarter. Swedbank AB bought a new stake in shares of Moderna during the first quarter valued at about $3,315,000. Atria Investments Inc acquired a new stake in Moderna in the first quarter worth about $1,063,000. Cetera Investment Advisers grew its position in Moderna by 584.2% in the 1st quarter. Cetera Investment Advisers now owns 68,390 shares of the company’s stock valued at $7,288,000 after buying an additional 58,394 shares in the last quarter. Finally, Cetera Advisors LLC increased its stake in Moderna by 198.1% during the 1st quarter. Cetera Advisors LLC now owns 12,669 shares of the company’s stock valued at $1,350,000 after buying an additional 8,419 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MRNA. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Barclays decreased their price target on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. Finally, Leerink Partners dropped their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $83.33.

Moderna Stock Performance

Shares of MRNA stock opened at $43.06 on Friday. The company has a market capitalization of $16.57 billion, a price-to-earnings ratio of -7.40 and a beta of 1.69. Moderna, Inc. has a 1-year low of $35.80 and a 1-year high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock’s fifty day simple moving average is $52.38 and its 200-day simple moving average is $91.36.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.39) EPS. On average, sell-side analysts predict that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 1,147 shares of company stock worth $76,245 in the last quarter. 15.70% of the stock is currently owned by corporate insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.